SCHEMBL22252383

SCHEMBL22252383

CCOC(=O)c1cnc2c(NC)cc(Cl)nn12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 8/20 0.45
▸ PDE4D Q08499 7/20 0.45
▸ NPC1 O15118 5/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ RAB9A P51151 4/20 0.42
▸ LMNA P02545 2/20 0.41
▸ KMT2A Q03164 1/20 0.40
▸ KDM4E B2RXH2 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA5A P35218 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ IDO1 P14902 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38
▸ ADORA2A P29274 1/20 0.38
▸ ADORA2B P29275 1/20 0.38
▸ ADORA1 P30542 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31245697 0.92 SMN1; SMN2 (0.40) TYK2PDE4DNPC1SMN1; SMN2RAB9A
SCHEMBL2357169 0.85 LMNA (0.44) NPC1SMN1; SMN2RAB9ALMNAKMT2A
SCHEMBL1202068 0.85 LMNA (0.44) NPC1SMN1; SMN2RAB9ALMNAKMT2A
SCHEMBL2358829 0.82 LMNA (0.42) NPC1SMN1; SMN2RAB9ALMNAKMT2A
SCHEMBL18405499 0.81 LMNA (0.41) NPC1SMN1; SMN2RAB9ALMNAKMT2A
SCHEMBL20504573 0.80 IDO1 (0.40) NPC1SMN1; SMN2RAB9ALMNAKMT2A
SCHEMBL18143583 0.79 ADORA1 (0.47) SMN1; SMN2LMNAKMT2AIDO1ADORA3
SCHEMBL25397592 0.77 LMNA (0.38) NPC1SMN1; SMN2RAB9ALMNAKMT2A
SCHEMBL14881448 0.76 KMT2A (0.44) NPC1SMN1; SMN2RAB9ALMNAKMT2A
SCHEMBL21185906 0.75 TYK2 (0.66) TYK2PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213571-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. 2025-07-03 — — US disclosed
EP-4493562-A1 TYK2 INHIBITORS AND USES THEREOF Alumis Inc. (US) 2025-01-22 — — EP disclosed
WO-2023178235-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. (US) 2023-09-21 — — WO disclosed
WO-2023178235-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. (US) 2023-09-21 — — WO disclosed
US-20220177486-A1 TYK2 INHIBITORS AND USES THEREOF ALUMIS INC. 2022-06-09 — — US disclosed
US-11174264-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-11-16 — — US disclosed
WO-2020185755-A1 TYK2 INHIBITORS AND USES THEREOF FRONTHERA U.S. PHARMACEUTICALS LLC (US) 2020-09-17 — — WO disclosed
WO-2020154474-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2020-07-30 — — WO disclosed
US-20200231594-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-07-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174264-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885PDE4D 4496/4885NPC1 4595/4885
US-20250213571-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK1, JAK2 TYK2 1/4885PDE4D 4067/4885NPC1 4835/4885
US-20200231594-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885PDE4D 4496/4885NPC1 4595/4885
US-20220177486-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK1, JAK2 TYK2 1/4885PDE4D 4067/4885NPC1 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback